Real-World FASENRA study completed in korea: safety under the microscope
NCT ID NCT05091333
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at the safety and effectiveness of FASENRA (benralizumab) in 51 Korean adults with severe eosinophilic asthma or eosinophilic granulomatosis with polyangiitis (EGPA). Researchers tracked side effects and how well the drug controlled symptoms during routine medical care. The goal was to confirm known safety information and catch any new issues.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- FASENRA (benralizumab)
- What this could lead to
- If results confirm safety, it supports continued use of FASENRA for controlling severe asthma and EGPA in real-world settings.
- What could go wrong
- This is a small, observational postmarketing study (51 people) with no control group, so it cannot prove cause and effect or detect rare side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
51 people
The number who actually took part.
- Started
-
Mar 2022
- Finished
-
Mar 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients aged 18 years and older, Patients with severe asthma with an eosinophilic phenotype eligible for first time treatment with FASENRA according to the indication as indicated in the locally approved prescribing information
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patients aged 18 years and older 2. Patients with severe asthma with an eosinophilic phenotype eligible for first time treatment with FASENRA according to the indication as indicated in the locally approved prescribing information 3. Patients with evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. Exclusion Criteria: 1. Hypersensitivity to the active substances or to any of the excipients 2. Current participation in any interventional trial
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Asthma, egpa(eosinophilic granulomatosis with polyangiitis) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Busan, South Korea
-
Research Site
Gangneung-si, South Korea
-
Research Site
Seoul, South Korea
-
Research Site
Suwon, South Korea
-
Research Site
Ulsan, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an injected biologic cut steroid Flare-Ups in a Tough-to-Treat asthma complication?
- Beyond breathing: could an asthma drug lift emotional burdens for patients and partners?
- Smart inhalers track Fasenra's asthma control over full dosing cycle
- CT scan could predict asthma drug success, saving months of trial and error
- New asthma drug shows promise in real-world greek study
- Real-World study checks if benralizumab tames severe asthma in taiwan